SF
TEVA icon

Synovus Financial’s Teva Pharmaceuticals TEVA Stock Holding History

Synovus Financial’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$303K Hold
15,005
– – ﹤0.01% 803
2025
Q2 		$251K Buy
15,005
+849
+6% +$13.7K ﹤0.01% 824
2025
Q1 		$218K Hold
14,156
– – ﹤0.01% 842
2024
Q4 		$312K Buy
14,156
+572
+4% +$10.4K ﹤0.01% 748
2024
Q3 		$245K Hold
13,584
– – ﹤0.01% 832
2024
Q2 		$221K Hold
13,584
– – ﹤0.01% 799
2024
Q1 		$192K Buy
13,584
+37
+0.3% +$466 ﹤0.01% 819
2023
Q4 		$141K Sell
13,547
-1,387
-9% -$12.9K ﹤0.01% 806
2023
Q3 		$152K Hold
14,934
– – ﹤0.01% 813
2023
Q2 		$112K Hold
14,934
– – ﹤0.01% 822
2023
Q1 		$132K Hold
14,934
– – ﹤0.01% 804
2022
Q4 		$136K Sell
14,934
-190
-1% -$1.66K ﹤0.01% 833
2022
Q3 		$122K Buy
15,124
+190
+1% +$1.68K ﹤0.01% 820
2022
Q2 		$112K Hold
14,934
– – ﹤0.01% 823
2022
Q1 		$140K Hold
14,934
– – ﹤0.01% 825
2021
Q4 		$120K Hold
14,934
– – ﹤0.01% 843
2021
Q3 		$146K Sell
14,934
-491
-3% -$4.6K ﹤0.01% 821
2021
Q2 		$153K Buy
15,425
+18
+0.1% +$191 ﹤0.01% 813
2021
Q1 		$177K Sell
15,407
-200
-1% -$2.29K ﹤0.01% 728
2020
Q4 		$151K Buy
15,607
+1,127
+8% +$10.8K ﹤0.01% 745
2020
Q3 		$130K Hold
14,480
– – ﹤0.01% 692
2020
Q2 		$179K Sell
14,480
-532
-4% -$6.02K ﹤0.01% 671
2020
Q1 		$135K Sell
15,012
-141
-0.9% -$1.45K ﹤0.01% 853
2019
Q4 		$149K Sell
15,153
-6,980
-32% -$62.3K ﹤0.01% 735
2019
Q3 		$151K Sell
22,133
-583
-3% -$4.47K ﹤0.01% 702
2019
Q2 		$209K Sell
22,716
-5,865
-21% -$70.7K ﹤0.01% 599
2019
Q1 		$448K Buy
28,581
+60
+0.2% +$1.06K 0.01% 458
2018
Q4 		$441K Sell
28,521
-1,089
-4% -$22.3K 0.01% 443
2018
Q3 		$639K Buy
29,610
+1,268
+4% +$29.4K 0.01% 417
2018
Q2 		$688K Buy
28,342
+440
+2% +$8.97K 0.01% 386
2018
Q1 		$475K Buy
27,902
+85
+0.3% +$1.66K 0.01% 439
2017
Q4 		$530K Buy
27,817
+6,029
+28% +$90.7K 0.01% 414
2017
Q3 		$384K Buy
21,788
+521
+2% +$11.7K 0.01% 448
2017
Q2 		$709K Buy
21,267
+30
+0.1% +$929 0.01% 353
2017
Q1 		$680K Buy
21,237
+3,100
+17% +$106K 0.01% 316
2016
Q4 		$656K Sell
18,137
-1,109
-6% -$44.3K 0.01% 308
2016
Q3 		$885K Sell
19,246
-185
-1% -$9.65K 0.02% 263
2016
Q2 		$977K Buy
19,431
+15,331
+374% +$816K 0.02% 265
2016
Q1 		$222K Sell
4,100
-100
-2% -$5.87K 0.01% 459
2015
Q4 		$277K Sell
4,200
-6,382
-60% -$394K 0.01% 398
2015
Q3 		$600K Sell
10,582
-1,527
-13% -$99K 0.02% 325
2015
Q2 		$716K Sell
12,109
-1,204
-9% -$74.3K 0.02% 309
2015
Q1 		$830K Sell
13,313
-1,624
-11% -$94.4K 0.02% 303
2014
Q4 		$863K Buy
14,937
+1,043
+8% +$58.1K 0.02% 295
2014
Q3 		$747K Buy
13,894
+1,830
+15% +$97K 0.02% 296
2014
Q2 		$635K Sell
12,064
-525
-4% -$26.8K 0.02% 293
2014
Q1 		$665K Sell
12,589
-2,151
-15% -$99.4K 0.02% 285
2013
Q4 		$592K Sell
14,740
-118
-0.8% -$4.65K 0.02% 286
2013
Q3 		$557K Sell
14,858
-1,514
-9% -$59.1K 0.02% 289
2013
Q2 		$643K Buy
+16,372
New +$638K 0.02% 271

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Synovus Financial's TEVA Position: Q3 2025 in Review

Synovus Financial held its Teva Pharmaceuticals (TEVA) position steady in Q3 2025 at 15,005 shares worth $303K. The position accounts for ﹤0.01% of the portfolio, ranked #803.

Synovus Financial first reported a position in TEVA in Q2 2013 and has held it in 50 quarters since. The position peaked at $977K in Q2 2016. 550 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • Synovus Financial held 15,005 shares of Teva Pharmaceuticals worth $303K as of Q3 2025.
  • Synovus Financial left its Teva Pharmaceuticals share count unchanged in Q3 2025.
  • Teva Pharmaceuticals made up ﹤0.01% of Synovus Financial's portfolio in Q3 2025, its #803 holding.
  • Synovus Financial first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 50 quarters since.
  • Synovus Financial's Teva Pharmaceuticals position peaked at $977K in Q2 2016.
  • 550 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2025.

Based on Synovus Financial's 13F filing for Q3 2025, filed 7 Nov 2025.